Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET. To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS protein
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]Seeking Alpha
- MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.MarketBeat
- Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective InhibitorGlobeNewswire
- Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 2/10/26 - Form 4
- 2/10/26 - Form SCHEDULE
- 2/9/26 - Form SCHEDULE
- RVMD's page on the SEC website